For Clinicians

Cystic fibrosis is identified later in India than in most high-income countries. The reasons are structural rather than clinical. CF is uncommon, it presents like conditions that are far more prevalent, and the two tests that settle the question, sweat chloride measurement and CFTR sequencing, are concentrated in a small number of tertiary centers.1

The diagnoses reached first are usually the reasonable ones to reach first. A child with chronic cough, chest radiograph changes, and poor weight gain in a setting where tuberculosis and malnutrition are common is being assessed sensibly when those are considered. What follows is not an argument that the condition is being overlooked through inattention. It is an account of what the delay costs, because that cost is what makes earlier detection worth pursuing.

Where the timeline sits

The median age at diagnosis in India falls between roughly two and ten and a half years, depending on the cohort. The comparable figures are about 2.6 months in the United States and 3.6 months in Europe, where newborn screening operates nationally.2 That gap is largely a function of screening infrastructure: without an immunoreactive trypsinogen program, every diagnosis depends on someone considering CF and being able to test for it.

What has usually happened by the time CF is confirmed

Children diagnosed late frequently present with complications that are themselves serious, and that earlier treatment would have largely prevented:34

• Pseudo-Bartter syndrome. Hypochloremic, hypokalemic metabolic alkalosis from salt loss through sweat, which in hot weather can be the presenting emergency.
• Advanced malnutrition. Hypoproteinemia with edema, anemia, and deficiency of the fat-soluble vitamins, reflecting years of unreplaced pancreatic enzyme deficiency.
• Established airway infection. Chronic Pseudomonas aeruginosa colonization already present at the point of diagnosis, after years without airway clearance.

The stakes are measurable. In one Indian series of infants with confirmed CF, 41 percent had died, at a median age of five months.6 Cystic fibrosis is treatable, and much of what makes it lethal early is time spent untreated.

This is the case for improving access to diagnosis. It is not a case against the clinicians working without that access.

Classic presentations

This section is useful whether or not CF-ARIA ever reaches clinical use. These are the presentations in which cystic fibrosis is worth adding to the differential, drawn from Indian cohort data rather than from Western case series.34

Atypical presentations

The table above describes the classic pediatric picture, and it is the one most clinicians in India are trained to recognize. Cystic fibrosis does not always present that way. A meaningful share of cases look nothing like it, and those are the cases most likely to be missed twice: once as children, and again as adults.

Milder CFTR genotypes, ones that leave some residual channel function, can delay presentation into adolescence or adulthood rather than infancy.34 Some of these patients are pancreatic sufficient: nutrition and growth are normal, and the disease shows itself only in the airway, as recurrent infection or bronchiectasis with no digestive complaint to prompt suspicion. An adult with bronchiectasis that has no identified cause, particularly if it involves the upper lobes or comes with chronic sinusitis and nasal polyps, is a reasonable candidate for testing.1

Congenital bilateral absence of the vas deferens, presenting as male infertility, can be the only clinical feature a patient with a milder genotype ever develops.1 Recurrent or otherwise unexplained pancreatitis belongs in the same group: it can be the sole manifestation of CFTR dysfunction, well before or entirely instead of any respiratory disease.1

What "CFTR-related disorder" means in practice

Some patients have a single-organ problem, most often CBAVD, recurrent pancreatitis, or diffuse bronchiectasis, that is attributable to CFTR dysfunction without meeting full diagnostic criteria for cystic fibrosis: the sweat chloride is typically normal or intermediate rather than clearly elevated.1 The practical implication is not that CF should be diagnosed anyway. It is that a single unexplained CFTR-associated problem, in isolation, is still worth a genetics or sweat chloride referral, and that a negative or borderline sweat test in that setting does not necessarily close the question the way it would in a patient with no suggestive findings at all.

Late diagnosis in adults is worth pursuing, not treated as moot because childhood has passed. Pancreatic enzyme replacement, airway clearance, and infection control still change the course of the disease when they start in adulthood rather than infancy, for the same reason earlier intervention helps children: they address a process that is still active, not one that has already run to completion.5

Distinguishing CF from its mimics

Every condition in the table below is a reasonable diagnosis to reach first in an Indian patient. Each is far more prevalent than cystic fibrosis, and each can produce a clinical picture that overlaps with it substantially. The question is not whether the first diagnosis was sound. It is what should prompt a second look when the response to treatment does not follow the expected course.

None of this argues for testing every child seen for tuberculosis, immune deficiency, or malnutrition. It argues for one thing: when the expected treatment does not work as expected, that non-response is itself a reason to widen the differential rather than intensify the original plan.

The order of operations

Suspicion is a starting point, not an answer. What follows is the sequence that carries a clinician from a reasonable suspicion to a result that can be acted on, and what to do at each point where it does not resolve cleanly.

1. Establish a reason to test

   A formal diagnosis of cystic fibrosis requires two things together: a compatible clinical presentation or risk factor (a positive newborn screen, an affected sibling, or one of the presentations described above), plus laboratory evidence of CFTR dysfunction. Neither is sufficient alone. Sweat chloride is the primary evidence, and it is the test almost every pathway starts with.910

2. Perform the sweat test

   CF-ARIA will soon be able to aid in the sweat test. See Sweat Testing and Evidence for the procedure itself and the requirements that determine whether a result can be trusted.

3. Interpret the result

   The thresholds are set out in that same section: 60 mmol/L or above supports CF, 30 to 59 mmol/L is intermediate, and 29 mmol/L or below makes CF unlikely. A single value rarely closes the question on its own. What happens next depends on which of those three bands the result falls into.

4. Act on the result

   A diagnostic value is ordinarily confirmed with a second sweat test on a separate day before treatment begins in earnest.9 An intermediate value triggers repeat testing, extended CFTR analysis, and consideration of the ancillary tests described below. A result that fails to collect enough sweat is not a result at all, and needs to be repeated rather than interpreted.

5. Settle the diagnosis, or name what remains unsettled

   The pathway ends in one of three places: CF confirmed, CF sufficiently unlikely that it is reasonable to look elsewhere, or a residual indeterminate picture that carries its own label and its own follow-up obligation rather than a discharge.

The intermediate band, repeat testing, and when to escalate

The 30 to 59 mmol/L band is the real clinical problem, not because the number is hard to measure, but because it does not resolve the question on its own. Three things follow from a result in this range: repeat the sweat test, proceed to extended CFTR analysis beyond a small targeted panel, and consider the ancillary tests below to build a fuller picture.59

If a repeat sweat test lands in the same band, that is useful information rather than a failed test. An intermediate result that reproduces is more likely to reflect a genuine, if partial, degree of CFTR dysfunction than a single anomalous reading, and it shifts the emphasis toward extended genetic analysis and toward the CFSPID or CRMS label described below, rather than toward repeating the sweat test indefinitely.

Quantity not sufficient, commonly abbreviated QNS, is a different problem and should be handled differently. It means too little sweat was collected to trust the number at all, and it is the commonest reason a sweat test needs repeating in neonates and small infants, whose sweat glands produce a smaller volume relative to the collection device.910 A QNS result is a reason to repeat the test, ideally at a center experienced in testing infants, rather than a reason to escalate straight to genetic testing in its place: it has not yet answered the question sweat chloride is meant to answer.

When repeated attempts still do not settle the picture

Occasionally a child accumulates a mix of intermediate, QNS, or discordant sweat results alongside an inconclusive genetic panel, with a clinical picture that still does not fit comfortably elsewhere. This is the point at which referral to a center able to perform extended CFTR sequencing, and where available, nasal potential difference or intestinal current measurement, adds more than another round of sweat testing.1

CFSPID, CRMS, and what happens next

A child with an intermediate or borderline picture that resolves into neither a clear diagnosis nor a clear exclusion is often labeled CFSPID (CF screen positive, inconclusive diagnosis) or CRMS (CFTR-related metabolic syndrome), terms used for the same indeterminate status.11 The label describes uncertainty, not a diagnosis of exclusion. It calls for structured follow-up, periodic reassessment of sweat chloride and clinical status through childhood, rather than discharge from care at the point the label is first applied.11

The honest limit to all of this is the same one described throughout this page. Every step above depends on reaching a center that can perform a valid sweat test in the first place. Where that access does not exist, the pathway stalls at the first step, and no amount of protocol resolves it downstream. That access gap, not the clinical reasoning, is the problem the rest of this page describes.5

Genetic testing in Indian patients: what a negative panel means

In an Indian patient whose clinical picture is consistent with cystic fibrosis, a negative result on a targeted CFTR mutation panel does not rule out the diagnosis. This is the single most consequential fact on this page for a case that has reached the genetics stage, because a negative panel is easy to read as closing the question when it has not.

The reason is where the panels were built. Commercial targeted panels test for a fixed list of variants selected because they are common in European populations. F508del, responsible for the large majority of CF alleles in those populations, is far less dominant in India, and cohorts do not agree on exactly how much less. A single-center series of 120 patients from four south Indian states put the F508del allele frequency at 27 percent.2 A pediatric cohort from western India found 28 percent (32 of 113 alleles).12 A multi-region study spanning several Indian states reported a range of 29 to 34 percent depending on geography, against roughly 70 to 80 percent in European cohorts.13 The cohorts disagree on the exact figure but agree on the direction: in every Indian series measured, a large minority to a majority of CF-causing alleles are not F508del, so a panel built to catch F508del and a short list of other European variants misses a correspondingly large share of Indian patients.

The Importance of Newborn Screening

Where newborn screening for CF exists, it is built around immunoreactive trypsinogen (IRT), a pancreatic enzyme precursor that is elevated in the blood of most infants with CF and can be measured from the same dried blood spot collected for other newborn conditions. The original algorithm, IRT/IRT, flags infants with a high initial IRT and repeats the test days later; those still elevated go on to sweat testing. Most programs now use IRT/DNA instead, adding a targeted CFTR panel after a first elevated IRT, an approach shown to outperform IRT/IRT and now generally preferred.2

Whichever algorithm is used, a positive newborn screen is not a diagnosis. It is an indication for sweat chloride testing, which remains the step that confirms or excludes CF.2 That dependency matters for a program built on IRT/DNA specifically: the DNA component only performs well if the panel behind it actually contains the variants circulating in the screened population, which is the same limitation described above for diagnostic genetic testing. A screening panel built for a different population's mutation spectrum will pass over infants whose variants are not on the list.

India has no national CF newborn screening program, and the reasons are not simply resource shortage. A review of the barriers specific to India identified limited awareness of newborn screening among providers and the public, heterogeneity in population genetics, socioeconomic resources, and health care infrastructure across the country, the funding scale required for a population of India's size, the need for adequate pre- and post-test counseling, and the difficulty of maintaining quality control across a program of that scope.2 India records roughly 24 million births a year, and the same genetic heterogeneity that complicates diagnostic testing also complicates an IRT/DNA program specifically, since no fixed panel can equitably cover the variant diversity across the country's regions.2 Reliable follow-up after a positive screen, itself a precondition for a program to do good rather than generate anxiety, is also harder to guarantee at national scale.2

This is the direct mechanism behind the diagnostic age gap already described. Newborn screening allows a diagnosis before any clinical sign has appeared; without it, every diagnosis still depends on a clinician encountering a symptomatic child, suspecting CF among more common alternatives, and being able to reach a sweat test. Screening does not remove that dependency by itself, either: an IRT-based program still ends at a sweat test, so a national screening program would need the same tertiary-center testing capacity described elsewhere on this page, not a replacement for it.

The first thirty days

A district pediatrician who has just confirmed a diagnosis of CF is often working without a specialist center nearby and without a checklist for what to do next. This section is meant to be that checklist: most of it can start immediately, at the district level, while referral to a specialist center is arranged in parallel.

1. Start pancreatic enzyme replacement, with food

   Most children with CF have pancreatic insufficiency and need enzyme replacement from diagnosis. Dosing is calculated in lipase units per kilogram per meal and expressed as a total in lipase units per kilogram per day, started low and titrated against stool character and weight gain.14 Enzymes are taken with the first bites of a fat-containing meal or snack, not after eating, so the enzyme is present in the gut alongside the food it digests.5 Dietary fat should not be restricted: it is the calorie source these children need most, and the enzyme dose exists so it can be absorbed rather than avoided.

   There is an upper limit to enzyme dosing

   Doses above roughly 6,000 lipase units/kg per meal have been associated with fibrosing colonopathy, a colonic stricture.14 Poor weight gain should prompt a review of technique and diet, not an escalation of the dose beyond what the guideline specifies.

2. Start salt supplementation

   Sweat glands in CF fail to reabsorb chloride and, with it, sodium, so children with CF lose more salt in sweat than their peers, and that loss scales with heat and exertion.910 In a hot climate, unreplaced loss can present as pseudo-Bartter syndrome (hypochloremic, hypokalemic metabolic alkalosis) or as hyponatremic dehydration. Routine salt supplementation, with extra salt during fever, heat, travel, or exertion, is inexpensive and should start alongside the diagnosis.

3. Start fat-soluble vitamin supplementation

   Fat malabsorption affects vitamins A, D, E, and K along with dietary fat, so all four are supplemented from diagnosis rather than after deficiency appears, and baseline blood levels are checked for a known starting point.5 A combined preparation is an acceptable substitute for four separate ones.

4. Start airway clearance immediately

   Airway clearance should begin as soon as the diagnosis is confirmed, not once a physiotherapist becomes available. Chest physical therapy, positioning combined with percussion, is usual for infants and young children, taught to a family member; older children can be taught breathing-based techniques directly. The technique has to be demonstrated in person and watched at least once, because errors in technique are not obvious to the person making them. Where no physiotherapist is available locally, a video-linked session with a specialist center, followed by a return demonstration, is preferable to no technique at all.

5. Order baseline investigations

   These establish the starting point against which every later visit is compared.5 Send a respiratory culture, from sputum where it can be obtained and from a throat or cough swab where it cannot, both to identify the organisms already present and to open a surveillance record. Take a chest radiograph for baseline structural change. Plot weight and height on a growth chart rather than simply recording them, since the trend is the most sensitive early marker of undertreatment. Check baseline liver enzymes, given the frequency of hepatobiliary involvement in CF, and a blood count, since anemia is common in advanced malnutrition. In older children and adolescents, check fasting glucose or arrange oral glucose tolerance testing, because the risk of CF-related diabetes rises with age. Send fecal elastase if pancreatic status has not already been established.

6. Set up infection prevention

   Patients with CF should not be seated together in a waiting room, scheduled back to back, or admitted to the same ward bay, even when their culture results look similar: cross-infection can occur between organisms nominally the same species but of different strains and virulence, so a child not yet colonized has the most to lose.15 Where separate scheduling is not possible, spacing appointments reduces the risk. Once diagnosis is established, respiratory culture is repeated at intervals as ongoing surveillance, so a new organism is caught while it may still be treatable.15

7. Set nutritional targets and track them

   Nutritional status predicts long-term lung function as directly as any respiratory measure: a child gaining weight and growing in height is usually also protecting the lungs, and a child who is not is losing ground even when the chest sounds unchanged.5 Where malnutrition is present at diagnosis, correcting it is not secondary to respiratory treatment. It is treatment.

8. Document what the next clinician will need

   What gets written down at diagnosis determines whether each later visit, at either site, builds on the last or starts over. At minimum, record the genotype if tested (or that it is pending), sweat chloride values with dates, organisms on culture, and current medicines with doses. A district clinician can deliver most of the care above day to day; the specialist center's role is periodic review and decisions that cannot be made locally.

Prognosis and what treatment achieves

The figure cited earlier on this page, that 41 percent of infants in one Indian series had died at a median age of five months, describes a population that reached care very late, largely without the interventions above already started.6 It is not a statement about what happens to a child whose disease is recognized and treated, and a family deserves that counterweight as much as they deserve the stakes.

In the United States, before CFTR modulator drugs existed, median predicted survival had already risen from 29.0 years in 1990 to 38.6 years in 2012, driven by exactly the supportive measures above: enzyme replacement, nutritional therapy, airway clearance, and treatment of infection, not by any drug that corrects the CFTR protein itself.16 Modulator therapy has since driven survival further, to a median of 68.0 years in the 2023 registry, but that gain is specific to modulator-eligible genotypes where the drugs are funded.16 Those figures describe a US registry population, not an estimate for an Indian child. What transfers is the pattern: supportive treatment alone, independent of modulator drugs, changes survival substantially.

Bronchiectasis, once established, is structural and does not reverse with treatment; the goal there is to prevent further damage, not undo what exists. Nutritional status and the frequency of respiratory infection are different: both respond to treatment started now, at any age and regardless of how late the diagnosis was made. A study of Egyptian children with CF, a resource setting comparable to much of India and one where modulator drugs were also not in use, found that three months of structured nutritional intervention measurably reduced the proportion of children with severe malnutrition and corrected anemia and low serum protein in most who had them.17 That is a change achievable with enzymes, calories, and monitoring alone, which matters because modulator drugs are genotype-dependent and, where available in India at all, are frequently unaffordable.

What a clinician can realistically tell a family at diagnosis is this: CF is lifelong, but the trajectory after diagnosis is not fixed by the trajectory before it. Nutritional status can be recovered even after early malnutrition, and fewer, better-treated infections change how the disease behaves over years. A precise survival figure for an Indian child started on treatment today does not yet exist, but treatment changes the outcome, in the parts of the disease within a clinician's control.

The reference standard

Any claim CF-ARIA makes has to be measured against quantitative pilocarpine iontophoresis, the established diagnostic standard for cystic fibrosis. A well-performed sweat test remains the benchmark, and the thresholds are unambiguous: a sweat chloride concentration of 60 mmol/L or above supports a diagnosis of CF, 30 to 59 mmol/L is intermediate and requires further evaluation, and 29 mmol/L or below makes CF unlikely at any age.9

Those numbers matter for two reasons. They are what a transdermal device must agree with, and the intermediate band is where agreement is hardest and most consequential.

Sweat testing in practice

The procedure itself is well established. Pilocarpine is driven into a small area of skin by a low-level current, stimulating local sweat production; sweat is collected over roughly thirty minutes onto gauze or into a coil, and chloride is quantified in the laboratory.910

Three requirements govern whether a result is usable, and each is a point at which the test becomes difficult to deliver outside a specialist center.

• Sufficient sweat. Guidelines specify minimum collected quantities, commonly cited as at least 75 mg on gauze or filter paper, or at least 15 microlitres by coil, together with an adequate sweat rate.910 Insufficient quantity is the dominant failure mode, and it is most frequent in neonates and small infants: precisely the group in whom early diagnosis matters most.
• A trained operator. Collection technique materially affects the result, and both evaporation and contamination can produce falsely elevated values.10
• Sustained volume. Guidelines recommend that laboratories perform a minimum number of tests annually to maintain proficiency, which is why low-volume sites produce results more likely to need repeating.9

Taken together, these requirements explain the geography. Equipment, consumables, trained staff, and enough throughput to stay proficient represent a standing institutional commitment, which is why sweat testing clusters in tertiary centers and why families elsewhere face distance and cost to reach it.1 The constraint is access, not the test.

Where CF-ARIA is intended to sit relative to the two established tests.

CF-ARIA is being developed at the Georgetown Nanoscience and Microtechnology Laboratory (GNuLab), also known as the Paranjape Lab, in the Department of Physics at Georgetown University. It is directed by Dr. Makarand (Mak) Paranjape, Associate Professor of Physics.

The laboratory works on functional microscale sensors, non-invasive transdermal diagnostic patches, and biomedical microdevices. CF-ARIA sits within an established line of work rather than being a departure from it: other projects include glucose sensors, neural probes, MRI contrast agents, and carbon nanotube sensors for gas monitoring and diabetes.

GNuLab occupies a 3,300 square foot shared-use clean room in Regents Hall, equipped for the fabrication and characterization of materials and electronic devices. It is open to researchers across the Georgetown University Main Campus and Medical Center as well as to external collaborators, who are trained and supported in their work by Dr. Jasper Nijdam. Projects are led by faculty research groups and carried out by postdoctoral fellows alongside graduate, undergraduate, and high-school students.